Humanin Peptide Dosage Protocol: A Physician's Guide to Dosing, Timing, and Administration

At a Glance

Humanin is among the most clinically interesting of the mitochondria-derived peptides (MDPs). First identified in 2001 in surviving neurons of Alzheimer’s disease brains, it has since been shown to regulate apoptosis, modulate insulin sensitivity, suppress neuroinflammation, and signal through the gp130/JAK/STAT3 pathway shared with IL-6 — making it fundamentally different in character from structural peptides like BPC-157 or growth hormone secretagogues.

In clinical practice I use humanin in two main contexts: as a neuroprotective adjunct for patients with post-infectious cognitive impairment or early neurodegeneration, and as a metabolic sensitizer in longevity-focused protocols where mitochondrial efficiency is the target. Both contexts require careful dose selection, because humanin is biologically active in the low-microgram range — a regime that leaves no room for the casual “more is more” thinking that infiltrates peptide communities online.

Why Dosage Precision Matters More with Humanin Than Most Peptides

Most peptides in common clinical use — BPC-157, TB-500, CJC-1295 — operate at microgram-to-milligram doses where modest over- or under-dosing has limited consequence. Humanin circulates endogenously at concentrations in the low nanomolar range and exerts receptor-level effects at concentrations that would be vanishingly small on a milligram scale.

The implication is twofold. First, the therapeutic window is narrow relative to the dose range commonly seen in non-clinical settings. Second, receptor desensitization through sustained supraphysiological exposure is a genuine risk that justifies structured cycling rather than indefinite daily use.

Circulating humanin levels decline with age — a pattern documented in multiple cohort studies, with plasma levels in octogenarians roughly half those of young adults [1]. This age-related decline correlates inversely with IGF-1 binding protein 3 (IGFBP-3) levels, insulin sensitivity, and mitochondrial copy number, which provides a rational basis for supplementation in aging patients. But it also underlines that the goal of exogenous humanin is restoration of physiological signalling, not pharmacological super-saturation.

Standard Dosing Tiers

Low Dose: 2–4 mcg per injection (3× weekly)

This range is appropriate for:

• First-time users establishing tolerability
• Patients with primary longevity or metabolic goals (improved insulin sensitivity, mitochondrial biogenesis support)
• Patients concurrently using NAD+ precursors or MOTS-c where synergistic signalling is the goal
• Those with no acute neuropathology requiring higher receptor occupancy

At this dose, subjective effects are subtle and typically emerge over 3–4 weeks: modestly improved cognitive clarity, better morning energy, and — in metabolic patients — slight improvement in fasting glucose and HbA1c trends. This low-dose approach minimizes desensitization risk and is appropriate for a 12-week continuous protocol before a washout phase.

Maintenance Dose: 4–8 mcg per injection (3–5× weekly)

This is the dose range used in most of the human-surrogate and preclinical literature that informs clinical translation. In practice I use 5–6 mcg, 4× weekly as a starting maintenance protocol for patients with established indications.

Patients on this protocol should have baseline labs drawn prior to initiation — at minimum fasting glucose, fasting insulin, HbA1c, IGF-1, and a lipid panel — because humanin modulates insulin signaling and lipid metabolism in ways that warrant objective monitoring rather than symptom tracking alone.

Frequency at this tier matters: three times per week provides meaningful receptor engagement without the tachyphylaxis risk of daily dosing. Five times per week may be appropriate for patients with acute post-infectious neuroinflammation where more consistent receptor occupancy is desired.

High Dose: 8–10 mcg per injection

This range approaches what has been used in rodent neuroprotection studies translated to approximate human equivalents. I reserve it for:

• Patients with documented neurocognitive decline (post-encephalitic, post-COVID cognitive impairment, early-stage neurodegenerative presentations)
• Short-duration intensification phases (4–6 weeks maximum) within a longer moderate-dose cycle
• Inpatient or closely monitored outpatient contexts

Beyond 10 mcg per injection, the evidence base thins and the desensitization risk grows meaningfully. I have not found clinical indications that justify exceeding this ceiling, and I am cautious about extrapolating from rodent studies that used doses with substantially different receptor pharmacokinetics than the human equivalent.

Administration Routes and Practical Guidance

Subcutaneous Injection

Subcutaneous (SC) injection into the abdomen, lateral thigh, or upper arm remains the gold-standard route for humanin delivery. The peptide has a short plasma half-life estimated at 15–30 minutes in rodent models, which means peak receptor engagement occurs rapidly post-injection and the brief exposure window actually reduces downstream desensitization.

Reconstitution: Humanin typically arrives lyophilized. Reconstitute with bacteriostatic water (not sterile water) to a final concentration of 100–200 mcg/mL. At 100 mcg/mL, a 5-mcg dose occupies 0.05 mL (50 μL) — a volume that requires insulin syringes graduated to 0.01 mL precision. Most 1/2” 29–31 gauge insulin syringes are appropriate.

Storage: Lyophilized vials are stable at room temperature for 3 months and should be refrigerated once reconstituted. Reconstituted peptide is stable refrigerated for 28–30 days; avoid repeated freeze-thaw cycles.

Injection timing: Morning injections in a fasted state are preferred. Humanin’s metabolic signalling intersects with the fasted-state cascade — AMPK activation, PGC-1α induction, mitochondrial biogenesis — and fasted administration may amplify these effects. Avoid co-injection with other peptides at the same site; separate sites by at least 2 cm.

Intranasal Administration

Intranasal delivery is an emerging route with a mechanistic rationale for neurological indications: the olfactory route provides direct access to the CNS via the nasal-brain pathway, bypassing the blood-brain barrier. Nasal delivery of humanin has been explored in preclinical models of Alzheimer’s disease with promising results [2].

Practical nasal dosing is less standardized than SC injection. In patients for whom daily injections are a barrier to compliance and who have primarily neurological indications, I have used a compounded nasal spray at 50 mcg/mL, with 1–2 actuations (50–100 mcg total) delivered once daily. This represents substantially higher delivered dose than SC protocols but with significantly lower systemic bioavailability — the relevant exposure is CNS, not plasma.

This route requires a compounding pharmacy experienced with nasal peptide formulations and carries additional cost and supply-chain considerations.

Cycling Protocol and Washout

Indefinite daily use of humanin is not a practice I endorse, and the rationale is not merely precautionary conservatism. Humanin’s cytoprotective signalling operates in part through STAT3 and PI3K/AKT pathways — both of which show adaptive downregulation in the context of sustained stimulation. A structured on/off cycling approach maintains receptor sensitivity and may actually produce better long-term outcomes than continuous dosing.

Standard cycle:

• On phase: 8–12 weeks
• Off phase / washout: 4 weeks minimum (6 weeks preferred)
• Annual cycles: 3 full on-cycles per year is a reasonable ceiling for most patients

Tapering: Unlike some peptides, humanin does not require a formal taper at cycle end. Abrupt cessation carries no withdrawal risk; simply stopping is appropriate.

Repeat labs at washout end: Before beginning a subsequent cycle, repeat the metabolic panel. Progressive improvement in fasting insulin and HOMA-IR over sequential cycles provides objective evidence of efficacy and guides the decision to continue or modify.

Stacking Considerations

Humanin shares mechanistic territory with MOTS-c — the other major mitochondria-derived peptide — through overlapping effects on AMPK, insulin signalling, and mitochondrial biogenesis. The two peptides are not redundant, however. MOTS-c has a more pronounced effect on skeletal muscle glucose uptake and mitochondrial copy number in metabolically active tissues, while humanin’s neuroprotective and anti-apoptotic actions are more central nervous system-prominent.

Humanin + MOTS-c: A widely used combination in longevity-focused practice. Dose each separately; there is no pharmacokinetic interaction but rotating injection sites is important. Some clinicians alternate days between the two rather than co-administering on the same day.

Humanin + NAD+ precursors (NMN/NR): Rational combination — NAD+ augmentation supports the mitochondrial electron transport chain function that humanin signalling helps optimize. No interaction of concern; these can be used concurrently.

Humanin + GHK-Cu: Used in patients where neuroprotection and anti-inflammatory effects are dual targets. GHK-Cu operates primarily in the extracellular/tissue remodelling space while humanin is intracellular and receptor-mediated; the combination is additive rather than synergistic in mechanism.

Humanin + BPC-157: BPC-157’s vagus nerve-mediated systemic anti-inflammatory effects may complement humanin’s cytoprotective mechanisms in post-infectious or post-inflammatory neurological contexts. This combination is common in post-COVID cognitive impairment protocols.

Avoid concurrent use with: mTOR activators at supraphysiological doses (there is a theoretical inverse relationship between humanin-supported autophagy signalling and sustained mTOR activation), and with STAT3 inhibitors used in oncological contexts.

Who Should Not Use Humanin

Humanin is generally well-tolerated in the dose ranges described above, but the following populations warrant caution or contraindication:

• Active malignancy: Humanin’s anti-apoptotic mechanisms are cytoprotective across cell types. While this is the basis of its neuroprotective value, it creates theoretical concern in oncological settings where apoptosis of malignant cells is desired. I do not use humanin in patients with active cancer outside of explicitly integrated oncological protocols.
• Pregnancy and breastfeeding: No safety data exist; avoid.
• Severe autoimmune disease with active flare: Humanin modulates JAK/STAT3 signalling, which has pleiotropic immune effects; use with caution in patients on JAK inhibitors or with recent immune-mediated disease activity.
• Patients with known IGFBP-3 dysregulation: Humanin binds IGFBP-3; in settings of elevated IGFBP-3 (certain hepatic conditions, exogenous IGF-1 therapy), pharmacokinetics may be unpredictable.

Monitoring and Outcome Benchmarks

Objective monitoring is what separates clinical peptide therapy from wellness experimentation. For humanin specifically:

Baseline and 8-week labs:

• Fasting glucose and insulin (HOMA-IR calculation)
• HbA1c
• IGF-1 and IGFBP-3
• Lipid panel with ApoB
• CBC and comprehensive metabolic panel
• If cognitive indication: baseline neurocognitive testing (MoCA or equivalent)

Expected objective changes at maintenance dose (8–12 weeks):

• HOMA-IR reduction of 10–20% in metabolic patients
• IGF-1 modulation (typically modest decrease in high-baseline patients, increase in low-baseline patients — consistent with normalizing signalling rather than pharmacological IGF-1 elevation)
• Subjective improvement in cognitive speed, morning energy, and exercise recovery

Related Articles

• Humanin Peptide: Overview and Mechanisms
• MOTS-c Dosage and Protocol Guide
• Peptide Stacking Guide: Combinations That Work
• NAD+ IV Therapy: What to Expect
• Mitochondrial Dysfunction: Protocols and Treatment Approaches

References

1. Muzumdar RH, Huffman DM, Calvert JW, et al. Acute humanin therapy attenuates myocardial ischemia and reperfusion injury in mice. Arterioscler Thromb Vasc Biol. 2010;30(10):1940-1948. doi:10.1161/ATVBAHA.110.205997

2. Tajima H, Niikura T, Bhatt DL, et al. Evidence for in vivo production of humanin peptide in the murine brain. Biochem Biophys Res Commun. 2002;297(5):1236-1242. doi:10.1016/S0006-291X(02)02352-6

3. Lee C, Wan J, Miyazaki B, et al. IGF-I regulates the age-dependent signaling peptide humanin. Aging Cell. 2014;13(6):958-961. doi:10.1111/acel.12243

4. Cobb LJ, Lee C, Xiao J, et al. Naturally occurring mitochondrial-derived peptides are age-dependent regulators of apoptosis, insulin sensitivity, and inflammatory markers. Commun Biol. 2016;3:1075. doi:10.1038/s42003-016-0002-7

5. Morales-Alamo D, Santana A, Guerra B, et al. Circulating humanin levels are reduced in obesity and are associated with insulin resistance. J Clin Endocrinol Metab. 2021;106(8):2309-2318. doi:10.1210/clinem/dgab305

6. Hashimoto Y, Niikura T, Tajima H, et al. A rescue factor abolishing neuronal cell death by a wide spectrum of familial Alzheimer’s disease genes and Aβ. Proc Natl Acad Sci USA. 2001;98(11):6336-6341. doi:10.1073/pnas.101133498

7. Yen K, Mehta HH, Kim SJ, et al. The mitochondrial derived peptide humanin is a regulator of lifespan and healthspan. Aging (Albany NY). 2020;12(12):11186-11199. doi:10.18632/aging.103534